Kura gets patent for clinical-stage ERK inhibitor

Kura Oncology, Inc. announced the issuance of a US patent for KO-947, its drug candidate targeting extracellular-signal-regulated kinases (ERK).

The new patent entitled “Inhibitors of ERK and Methods of Use” covers KO-947 and structurally-related compounds as well as methods of using the compounds for the treatment of diseases including cancer.

“We believe KO-947 holds much promise as a potential therapeutic, and we were pleased to have advanced it into Phase 1 clinical testing earlier this month,” said Kura Oncology CEO Troy Wilson.

“Issuance of this composition of matter patent is an important development for Kura and the program.”